A Modified Haploidentical Nonmyeloablative Transplantation without T Cell Depletion for High-Risk Acute Leukemia: Successful Engraftment and Mild GVHD

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 8, 2009, Pages 930-937

  Guo, Mei ^a   Sun, Zhao ^b   Sun, Qi Yun ^a   Han, Qin ^b   Yu, Chang Lin ^a   Wang, Dan Hong ^a   Qiao, Jian Hui ^a   Chen, Bin ^b   Sun, Wan Jun ^a   Hu, Kai Xun ^a   Liu, Guang Xian ^a   Liu, Bing ^a   Zhao, Robert Chunhua ^b   Ai, Huisheng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Center of Excellence in Tissue Engineering   (China)

Author keywords

Acute leukemia; GVHD; Haploidentical nonmyeloablative transplantation; Mesenchymal stem cell; Relapse

Indexed keywords

BASILIXIMAB; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; HLA ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; APHERESIS; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CELLULAR IMMUNITY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; MALE; MEDICAL DECISION MAKING; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUTROPHIL COUNT; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; PROBABILITY; PROPHYLAXIS; SCHOOL CHILD; T CELL DEPLETION; THROMBOCYTE COUNT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGED; CHEMOPREVENTION; COMBINED MODALITY THERAPY; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HAPLOTYPES; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK ASSESSMENT; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649859227     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.04.006     Document Type: Article

References (42)

1. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15 (1997) 1767-1777
2. Spitzer T.R. Haploidentical stem cell transplantation: the always present but overlooked donor. Hematology Am Soc Hematol Educ Program (2005) 390-395
3. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
4. Shimazaki C., Ochiai N., Uchida R., et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism. Blood 101 (2003) 3334-3336
5. Nakai K., Mineishi S., Kami M., Kanda Y., Tanosaki R., and Takaue Y. The feasibility of reduced-intensity allogeneic hematopoietic stem cell transplantation from a related donor with HLA one-antigen with or without one-allele mismatch. Haematologica 88 (2003) 115-117
6. Rizzieri D.A., Koh L.P., Long G.D., et al. Partial matarched Nonmyeloablative allogenetic transplantation: clinical ouecome and immune reconstitution. J Clin Oncol 25 (2007) 690-697
7. + T-cell-depleted graft. Bone Marrow Transplant 31 (2003) 121-128
8. Bethge W.A., Haegele M., Faul C., et al. Haploidentical allogeneic hematopoietic cell transplantation in adult with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol 34 (2006) 1746-1752
9. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophophamide. Biol Blood Marrow Transplant 8 (2002) 377-386
10. Blazsek I., Chagraoui J., and Peault B. Ontogenic emergence of the hematon, a morphogenetic stromal unit that supports multipotential hematopoietic progenitors in mouse bone marrow. Blood 96 (2000) 3763-3771
11. Almeida-Porada G., Porada C.D., Tran N., and Zanjani E.D. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 95 (2000) 3620-3627
12. Anklesaria P., Kase K., Glowacki J., et al. Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. Proc Natl Acad Sci USA 84 (1987) 7681-7685
13. (+) cells in NOD/SCID mice. Exp Hematol 30 (2002) 870-878
14. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
15. Jiang X.X., Zhang Y., Liu B., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105 (2005) 4120-4126
16. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
17. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., and Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111 (2007) 1327-1333
18. Nauta A.J., and Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110 (2007) 3499-3506
19. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
20. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110 (2007) 2764-2767
21. - mesenchymal stem cells: feasibility and safety from monkey to human. Stem Cells Dev 15 (2006) 349-357
22. Liu L.H., Sun Q.Y., Hu K.X., et al. Establishment of Rhesus model for haploidentical hematopoietic stem cell transplantation with nonmyeloablative conditioning. Zhonghua Xue Ye Xue Za Zhi 26 (2005) 385-388
23. Majumdar M.K., Thiede M.A., Mosca J.D., et al. Phenotypic and functional comparison of culture of marrow-derived mesenchymal stem cells and stromal cells. J Cell Physiol 176 (1998) 57-66
24. Fang B., Liao L., Shi M., Yang S., and Zhao R.C. Multipotency of Flk1CD34 progenitors derived from human fetal bone marrow. J Lab Clin Med 143 (2004) 230-240
25. Zhao Z., Liao L., Cao Y., Jiang X., and Zhao R.C. Establishment and properties of fetal dermis-derived mesenchymal stem cell lines: plasticity in vitro and hematopoietic protection in vivo. Bone Marrow Transplant 36 (2005) 355-365
26. Hui-Sheng A., Zhao R.C.-H., Guo M., et al. Mixed hematopoietic chimerism-a new strategy for preventing GVHD in nonmyeloablative allogeneic stem cell transplantation. Exp Hematol 30 (2002) 119
27. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
28. Mehta J., Singhal S., Gee A.P., et al. Bone marrow transplantation from partial HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 33 (2004) 389-396
29. Kanda Y., Chiba S., Hirai H., et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102 (2003) 1541-1547
30. Tamaki H., Ikegame K., Kawakami1 M., et al. Engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 17 (2003) 2052-2054
31. Deeg H.J. How I treat refractory acute GVHD. Blood 109 (2007) 4119-4126
32. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
33. Mohty M., Bay J.O., Faucher C., et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102 (2003) 470-476
34. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104 (2004) 1559-1564
35. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., and Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108 (2006) 2114-2120
36. Shaffer J., Villard J., Means T.K., et al. Regulary T-cell recovery in receipients of Haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-Cd2 mab, Medi-507, with or without fludarabie. Exp Hematol 35 (2007) 1140-1152
37. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
38. Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cell in hematologic malignancy patients. Biol Blood Marrow Transplant 11 (2005) 389-398
39. Handgretinger R., Chen X., Pfeiffer M., et al. Feasibility and outcome of reduced intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 1106 (2007) 279-289
40. Fung H.C., Stein A., Slovak M., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 9 (2003) 766-771
41. Koç O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18 (2000) 307-316
42. Gao J., Dennis J.E., Muzic R.F., et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissue Organs 169 (2001) 12-20